Oramed Pharmaceuticals Stock News

Gainers Seritage Growth Properties (NYSE: SRG) shares surged 80.3% to settle at $10.96 after the company appointed Adam Metz as Chairman. Preliminary proxy materials also indicated the board recomme

A reassuring letter to shareholders has the biotech's stock jumping today.

U.S. stocks traded slightly higher toward the end of trading as investors digested the recent jobs report for the month of June. The Dow traded up 0.24% to 31,460 while the NASDAQ rose 0.28% to 11,65

A reassuring letter to shareholders has the biotech's stock jumping today.

Gainers Fujian Blue Hat Interactive Entertainment Technology Ltd. (NASDAQ: BHAT) shares jumped 263% to $2.73 on Thursday. Blue Hat Interactive terminated its previously proposed shelf takedown offer

Oramed is developing oral insulin in a phase 3 trial, data this year. Nobody has been able to deliver insulin orally in adequate quantity.

NEW YORK, March 10, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Chief Executive Officer Nadav Kidron will present a live…

Upgrades Roth Capital upgraded the previous rating for Denbury Inc (NYSE:DEN) from Neutral to Buy. For the third quarter, Denbury had an EPS of $0.74, compared to year-ago quarter EPS of $0.05. The s

BALTIMORE--(BUSINESS WIRE)--MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical-stage pharmaceutical company committed to extending healthy lifespan, announced toda

Oramed Pharmaceuticals Inc. ORMP, -11.40% said Wednesday its Oravax Medical subsidiary has signed an agreement with Vietnam-based Tan Thanh Holdings Investment Joint Stock Co. to pre-purchase 10 milli

Calamos Advisors LLC bought a new position in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) in the third quarter, HoldingsChannel.com reports. The institutional investor bought 132,145 shares of the biotechnology companys stock, valued at approximately $2,906,000. A number of other hedge funds have also modified their holdings of the business. BlackRock Inc. increased its holdings in shares of []

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) gapped up prior to trading on Tuesday . The stock had previously closed at $15.58, but opened at $16.56. Oramed Pharmaceuticals shares last traded at $16.54, with a volume of 3,443 shares trading hands. ORMP has been the topic of several analyst reports. HC Wainwright reiterated a buy rating and issued []

Goldman Sachs Group Inc. raised its holdings in Oramed Pharmaceuticals Inc. by 77.4% during the 2nd quarter, according to its most recent filing with the Securities and

Goldman Sachs Group Inc. raised its holdings in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) by 77.4% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 35,055 shares of the biotechnology companys stock after buying an additional 15,300 shares during the quarter. Goldman Sachs Group Inc. owned [] The post Goldman Sachs Group Inc. Buys 15,300 Shares of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) appeared first on ETF Daily News .